LQDA trades 7.9% above Wall Street's consensus target of $74.83.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LQDA achieves its forward estimates and maintains a stable P/E multiple of 24.6x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Liquidia Corporation (LQDA) has a Wall Street consensus price target of $74.83, based on estimates from 7 covering analysts. With the stock currently trading at $81.23, this represents a potential downside of -7.9%. The company has a market capitalization of $7.22B.
Analyst price targets range from a low of $60.00 to a high of $109.00, representing a 65% spread in expectations. The median target of $71.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LQDA trades at a trailing P/E of -101.5x and forward P/E of 24.6x. Analysts expect EPS to grow +1394.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.75, with bear and bull scenarios of $5.51 and $11.53 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
UTHRUnited Therapeutics Corporation | $23.9B | $563.70 | $636.83 | +13.0% | Buy | 20.1x | 30 |
MNKDMannKind Corporation | $1.3B | $4.22 | $8.50 | +101.4% | Buy | — | 19 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
INSMInsmed Incorporated | $24.5B | $112.84 | $204.42 | +81.2% | Buy | — | 35 |
NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
PBYIPuma Biotechnology, Inc. | $405M | $7.96 | — | — | Buy | 27.4x | 19 |
KALAKALA BIO, Inc. | $33M | $1.51 | $18.25 | +1108.6% | Buy | — | 9 |
JNJJohnson & Johnson | $643.3B | $267.24 | $253.42 | -5.2% | Buy | 23.1x | 40 |
MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
Quick answers to the most common questions about buying LQDA stock.
Wall Street's consensus price target for LQDA is $74.83, -7.9% from its current price of $81.23. The below-market target from 7 analysts suggests limited near-term appreciation.
LQDA has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $74.83 implies -7.9% downside from current levels.
LQDA trades at a forward P/E of 24.6361x, representing a moderate valuation. With analysts targeting $74.83 (-7.9% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $109 for LQDA, while the most conservative target is $60. The consensus of $74.83 represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LQDA is moderately covered, with 7 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LQDA stock forecast based on 7 Wall Street analysts shows a consensus price target of $74.83, with estimates ranging from $60 (bear case) to $109 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.
Our quantitative valuation model calculates LQDA's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
LQDA trades at a forward P/E ratio of 24.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on LQDA, with 1 Sell ratings and a price target of $74.83 (-7.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LQDA analyst price targets range from $60 to $109, a 65% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $74.83 consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.